PTAB Invalidates Humira Patent In Coherus Challenge

Law360, New York (May 17, 2017, 5:11 PM EDT) -- The Patent Trial and Appeal Board invalidated a key patent for AbbVie Biotechnology Ltd.’s mega-blockbuster autoimmune disease drug Humira on Tuesday, finding the patent would have been obvious at the time of the invention.

The PTAB’s decision in inter partes review is a victory for Coherus BioSciences Inc., a California biosimilars company that, according to published reports, has been looking to launch a copycat of Humira, the world’s best-selling pharmaceutical.

The patent covers a Humira dosing regimen to treat rheumatoid arthritis. Coherus argued it would have been obvious in light of two journal articles that described the results of clinical studies...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!